AP
GSK icon

Advisor Partners’s GSK GSK Stock Holding History

Advisor Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$870K Buy
15,990
+1,355
+9% +$74.8K 0.06% 328
2022
Q1 		$797K Buy
14,635
+271
+2% +$14.7K 0.05% 367
2021
Q4 		$792K Buy
14,364
+1,494
+12% +$77.7K 0.05% 373
2021
Q3 		$615K Buy
12,870
+1,872
+17% +$94K 0.04% 425
2021
Q2 		$547K Buy
10,998
+180
+2% +$8.65K 0.04% 474
2021
Q1 		$483K Sell
10,818
-1,476
-12% -$67K 0.03% 489
2020
Q4 		$566K Sell
12,294
-1,346
-10% -$61.8K 0.04% 421
2020
Q3 		$642K Sell
13,640
-2,564
-16% -$128K 0.06% 313
2020
Q2 		$826K Buy
16,204
+4,890
+43% +$251K 0.08% 230
2020
Q1 		$535K Sell
11,314
-4,316
-28% -$230K 0.06% 272
2019
Q4 		$930K Buy
15,630
+1,949
+14% +$108K 0.1% 216
2019
Q3 		$730K Buy
13,681
+2,417
+21% +$124K 0.09% 245
2019
Q2 		$563K Sell
11,264
-544
-5% -$27.3K 0.07% 286
2019
Q1 		$617K Buy
11,808
+718
+6% +$35.9K 0.08% 253
2018
Q4 		$530K Sell
11,090
-2,322
-17% -$114K 0.08% 262
2018
Q3 		$673K Buy
13,412
+2,770
+26% +$141K 0.09% 235
2018
Q2 		$536K Buy
10,642
+3,313
+45% +$167K 0.09% 262
2018
Q1 		$358K Buy
+7,329
New +$341K 0.07% 346
2016
Q1 		– Sell
-9,493
Closed -$479K – 384
2015
Q4 		$479K Buy
9,493
+447
+5% +$22.8K 0.16% 151
2015
Q3 		$435K Sell
9,046
-457
-5% -$23.8K 0.18% 142
2015
Q2 		$497K Buy
9,503
+885
+10% +$49.8K 0.19% 156
2015
Q1 		$497K Buy
8,618
+106
+1% +$6.08K 0.21% 138
2014
Q4 		$482K Sell
8,512
-302
-3% -$16.9K 0.21% 138
2014
Q3 		$506K Sell
8,814
-336
-4% -$20.6K 0.29% 100
2014
Q2 		$612K Sell
9,150
-70
-0.8% -$4.74K 0.3% 106
2014
Q1 		$616K Buy
9,220
+102
+1% +$6.9K 0.34% 94
2013
Q4 		$609K Buy
9,118
+268
+3% +$17.4K 0.35% 92
2013
Q3 		$555K Buy
8,850
+372
+4% +$23.9K 0.4% 84
2013
Q2 		$530K Buy
+8,478
New +$538K 0.43% 74

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $58.9B AUM 51.73% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Advisor Partners's GSK Position: Q2 2022 in Review

Advisor Partners increased its GSK (GSK) stake by 9.3% in Q2 2022, buying an estimated $74.8K and bringing the position to 15,990 shares worth $870K. The position accounts for 0.06% of the portfolio, ranked #328.

Advisor Partners first reported a position in GSK in Q2 2013 and has held it in 29 quarters since. The position peaked at $930K in Q4 2019. 901 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

  • Advisor Partners held 15,990 shares of GSK worth $870K as of Q2 2022.
  • Advisor Partners bought 1,355 GSK shares in Q2 2022, an estimated $74.8K.
  • GSK made up 0.06% of Advisor Partners's portfolio in Q2 2022, its #328 holding.
  • Advisor Partners first reported a position in GSK in Q2 2013 and has held it in 29 quarters since.
  • Advisor Partners's GSK position peaked at $930K in Q4 2019.
  • 901 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.